Journal article
Serum levels of anti-PspA and anti-PspC IgG decrease with age and do not correlate with susceptibility to experimental human pneumococcal colonization
- Abstract:
- Older adults are at increased risk of pneumococcal disease. This work aims to evaluate whether there is any decrease in serum IgG against variants of the antigens Pneumococcal surface protein A (PspA) and Pneumococcal surface protein C (PspC) in healthy adults with increasing age. Levels of IgG against PspA and PspC variants were determined by ELISA in serum samples comparing volunteers 18-30 years of age with volunteers who were 50-70+ before and after an experimental pneumococcal colonization challenge. The serotype 6B strain used in the challenge belongs to a minor group of pneumococcal isolates expressing two PspC variants. There was a decrease in levels of IgG with increasing age for the most common PspA variants and for all PspC variants analyzed. No correlation was found between basal levels of IgG against these antigens and protection against colonization. There was an increase in levels of IgG against PspA variants that are more cross-reactive with the variant expressed by the challenge strain post challenge in younger individuals who became colonized. Since the challenge strain used in our study expresses two different PspC variants, an increase in serum IgG against all PspC variants tested was observed in younger individuals who became colonized. For some of the antigen variants tested, a decrease in serum IgG was observed in young volunteers who were challenged but did not become colonized. Serum IgG antibodies against PspA and PspC variants thus decrease with age in healthy adults, but there is no correlation between levels of IgG against these antigens and protection against human experimental colonization. Though no correlation between naturally induced serum IgG antibodies against PspA and PspC and protection against colonization was observed, these results do not rule out the protective potential of these antigens as vaccines against pneumococcal infections
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.2MB, Terms of use)
-
- Publisher copy:
- 10.1371/journal.pone.0247056
- Publication website:
- https://archive.lstmed.ac.uk/17153/1/journal.pone.0247056.pdf
Authors
+ Medical Research Council
More from this funder
- Funder identifier:
- 10.13039/501100000265
- Grant:
- MR/M011569/1
+ Bill and Melinda Gates Foundation
More from this funder
- Funder identifier:
- 10.13039/100000865
- Grant:
- OPP1117728
+ Fundação de Amparo à Pesquisa do Estado de São Paulo
More from this funder
- Funder identifier:
- 10.13039/501100001807
- Grant:
- 2018/ 25165-6
+ Conselho Nacional de Desenvolvimento Científico e Tecnológico
More from this funder
- Funder identifier:
- 10.13039/501100003593
- Grant:
- 303072/2018-0
- Publisher:
- Public Library of Science
- Journal:
- PLoS ONE More from this journal
- Volume:
- 16
- Issue:
- 2
- Pages:
- e0247056-e0247056
- Publication date:
- 2021-02-12
- DOI:
- EISSN:
-
1932-6203
- ISSN:
-
1932-6203
- Language:
-
English
- Keywords:
- Pubs id:
-
1274168
- Local pid:
-
pubs:1274168
- Source identifiers:
-
W3126311563
- Deposit date:
-
2026-04-28
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2021
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record